ArticleFrontiers in oncology2025
Primary mucinous carcinoma of the skin with co-expression of TRPS1 and GATA3: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary cutaneous mucinous carcinoma (PCMC) is a rare malignant neoplasm, with approximately 450 cases reported worldwide to date. Its histological features closely resemble those of mucinous carcinoma of the breast, posing significant diagnostic challenges. We report a case of PCMC occurring at the upper margin of the eyelid in a 65-year-old male who presented with a painless, progressively enlarging mass over a four-year period. Histopathological examination following surgical excision confirmed the diagnosis of PCMC, with immunohistochemical staining demonstrating co-expression of TRPS1 and GATA3. This case highlights several key clinical and pathological characteristics of PCMC. The tumor typically affects middle-aged to elderly males and demonstrates low metastatic potential but a high rate of local recurrence. Histologically, it is difficult to distinguish from cutaneous metastatic mucinous carcinoma (MMC), particularly of breast origin. In this context, the co-expression of TRPS1 and GATA3 necessitates careful interpretation, as these markers are not exclusive to PCMC. The diagnostic utility of TRPS1 lies not in its individual specificity, but rather in its combined use with other markers such as GATA3. Radical surgical excision remains the mainstay of treatment, with adjuvant endocrine therapy considered in ER/PR-positive cases. Compared to cutaneous MMC, PCMC generally carries a more favorable prognosis, reinforcing the importance of early and accurate diagnosis. Ultimately, the diagnosis of PCMC relies on a comprehensive evaluation that integrates clinical presentation, imaging findings, histological architecture, and immunohistochemical profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.